dc.contributor.author |
Flanagan, Katie L |
|
dc.contributor.author |
Best, Emma |
|
dc.contributor.author |
Crawford, Nigel W |
|
dc.contributor.author |
Giles, Michelle |
|
dc.contributor.author |
Koirala, Archana |
|
dc.contributor.author |
Macartney, Kristine |
|
dc.contributor.author |
Russell, Fiona |
|
dc.contributor.author |
Teh, Benjamin W |
|
dc.contributor.author |
Wen, Sophie Ch |
|
dc.date.accessioned |
2020-12-08T23:17:06Z |
|
dc.date.available |
2020-12-08T23:17:06Z |
|
dc.date.issued |
2020-1 |
|
dc.identifier.citation |
Frontiers in immunology 11:579250 Jan 2020 |
|
dc.identifier.issn |
1664-3224 |
|
dc.identifier.uri |
http://hdl.handle.net/2292/53907 |
|
dc.description.abstract |
There are currently around 200 SARS-CoV-2 candidate vaccines in preclinical and clinical trials throughout the world. The various candidates employ a range of vaccine strategies including some novel approaches. Currently, the goal is to prove that they are safe and immunogenic in humans (phase 1/2 studies) with several now advancing into phase 2 and 3 trials to demonstrate efficacy and gather comprehensive data on safety. It is highly likely that many vaccines will be shown to stimulate antibody and T cell responses in healthy individuals and have an acceptable safety profile, but the key will be to confirm that they protect against COVID-19. There is much hope that SARS-CoV-2 vaccines will be rolled out to the entire world to contain the pandemic and avert its most damaging impacts. However, in all likelihood this will initially require a targeted approach toward key vulnerable groups. Collaborative efforts are underway to ensure manufacturing can occur at the unprecedented scale and speed required to immunize billions of people. Ensuring deployment also occurs equitably across the globe will be critical. Careful evaluation and ongoing surveillance for safety will be required to address theoretical concerns regarding immune enhancement seen in previous contexts. Herein, we review the current knowledge about the immune response to this novel virus as it pertains to the design of effective and safe SARS-CoV-2 vaccines and the range of novel and established approaches to vaccine development being taken. We provide details of some of the frontrunner vaccines and discuss potential issues including adverse effects, scale-up and delivery. |
|
dc.format.medium |
Electronic-eCollection |
|
dc.language |
eng |
|
dc.publisher |
Frontiers Media SA |
|
dc.relation.ispartofseries |
Frontiers in immunology |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Immunology |
|
dc.subject |
antibody dependent enhancement (ADE) |
|
dc.subject |
adverse events of special interest (AESI) |
|
dc.subject |
bacillus Calmette-Guerin (BCG) |
|
dc.subject |
cell mediated immunity |
|
dc.subject |
Coalition for Epidemic Preparedness Innovations (CEPI) |
|
dc.subject |
innate immunity |
|
dc.subject |
neutralizing antibodies |
|
dc.subject |
spike protein |
|
dc.subject |
ACUTE RESPIRATORY SYNDROME |
|
dc.subject |
ANTIBODY-DEPENDENT ENHANCEMENT |
|
dc.subject |
ORIGINAL ANTIGENIC SIN |
|
dc.subject |
IMMUNE-RESPONSE |
|
dc.subject |
SARS-COV |
|
dc.subject |
NONSPECIFIC PROTECTION |
|
dc.subject |
EPIDEMIC PREPAREDNESS |
|
dc.subject |
CELL RESPONSES |
|
dc.subject |
GENETIC DRIFT |
|
dc.subject |
VACCINATION |
|
dc.subject |
1107 Immunology |
|
dc.subject |
1108 Medical Microbiology |
|
dc.title |
Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.3389/fimmu.2020.579250 |
|
pubs.begin-page |
579250 |
|
pubs.volume |
11 |
|
dc.date.updated |
2020-11-17T21:01:17Z |
|
dc.rights.holder |
Copyright: The authors |
en |
pubs.author-url |
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000578292500001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=6e41486220adb198d0efde5a3b153e7d |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
|
pubs.subtype |
review-article |
|
pubs.subtype |
Review |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
820382 |
|
dc.identifier.eissn |
1664-3224 |
|
pubs.number |
ARTN 579250 |
|
pubs.online-publication-date |
2020-10-2 |
|